A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in m...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.857440/full |
| _version_ | 1819023276762988544 |
|---|---|
| author | Ariane Volkmann Gerrit Koopman Petra Mooij Ernst J. Verschoor Babs E. Verstrepen Willy M. J. M. Bogers Manja Idorn Søren R. Paludan Søren Vang Morten A. Nielsen Morten A. Nielsen Adam F. Sander Adam F. Sander Adam F. Sander Carolin Schmittwolf Hubertus Hochrein Paul Chaplin |
| author_facet | Ariane Volkmann Gerrit Koopman Petra Mooij Ernst J. Verschoor Babs E. Verstrepen Willy M. J. M. Bogers Manja Idorn Søren R. Paludan Søren Vang Morten A. Nielsen Morten A. Nielsen Adam F. Sander Adam F. Sander Adam F. Sander Carolin Schmittwolf Hubertus Hochrein Paul Chaplin |
| author_sort | Ariane Volkmann |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing. |
| first_indexed | 2024-12-21T04:36:19Z |
| format | Article |
| id | doaj.art-70276a3707f448aaac6b86a678a0b8dd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T04:36:19Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-70276a3707f448aaac6b86a678a0b8dd2022-12-21T19:15:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.857440857440A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesAriane Volkmann0Gerrit Koopman1Petra Mooij2Ernst J. Verschoor3Babs E. Verstrepen4Willy M. J. M. Bogers5Manja Idorn6Søren R. Paludan7Søren Vang8Morten A. Nielsen9Morten A. Nielsen10Adam F. Sander11Adam F. Sander12Adam F. Sander13Carolin Schmittwolf14Hubertus Hochrein15Paul Chaplin16Bavarian Nordic GmbH, Martinsried, GermanyDepartment of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsDepartment of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsDepartment of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsDepartment of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsDepartment of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsDepartment of Biomedicine, Aarhus University, Aarhus, DenmarkDepartment of Biomedicine, Aarhus University, Aarhus, DenmarkDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, DenmarkCentre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Infectious Disease, Copenhagen University Hospital, Copenhagen, DenmarkCentre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Infectious Disease, Copenhagen University Hospital, Copenhagen, DenmarkAdaptVac Aps, Hørsholm, DenmarkBavarian Nordic GmbH, Martinsried, GermanyBavarian Nordic GmbH, Martinsried, GermanyBavarian Nordic A/S, Hellerup, DenmarkSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.https://www.frontiersin.org/articles/10.3389/fimmu.2022.857440/fullvirus-like particles (VLP)SARS-CoV-2coronaCOVID-19broad neutralizing antibodiesprotection |
| spellingShingle | Ariane Volkmann Gerrit Koopman Petra Mooij Ernst J. Verschoor Babs E. Verstrepen Willy M. J. M. Bogers Manja Idorn Søren R. Paludan Søren Vang Morten A. Nielsen Morten A. Nielsen Adam F. Sander Adam F. Sander Adam F. Sander Carolin Schmittwolf Hubertus Hochrein Paul Chaplin A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques Frontiers in Immunology virus-like particles (VLP) SARS-CoV-2 corona COVID-19 broad neutralizing antibodies protection |
| title | A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques |
| title_full | A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques |
| title_fullStr | A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques |
| title_full_unstemmed | A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques |
| title_short | A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques |
| title_sort | capsid virus like particle based sars cov 2 vaccine induces high levels of antibodies and protects rhesus macaques |
| topic | virus-like particles (VLP) SARS-CoV-2 corona COVID-19 broad neutralizing antibodies protection |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.857440/full |
| work_keys_str_mv | AT arianevolkmann acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT gerritkoopman acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT petramooij acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT ernstjverschoor acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT babseverstrepen acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT willymjmbogers acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT manjaidorn acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT sørenrpaludan acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT sørenvang acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT mortenanielsen acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT mortenanielsen acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT carolinschmittwolf acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT hubertushochrein acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT paulchaplin acapsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT arianevolkmann capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT gerritkoopman capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT petramooij capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT ernstjverschoor capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT babseverstrepen capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT willymjmbogers capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT manjaidorn capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT sørenrpaludan capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT sørenvang capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT mortenanielsen capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT mortenanielsen capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT adamfsander capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT carolinschmittwolf capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT hubertushochrein capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques AT paulchaplin capsidviruslikeparticlebasedsarscov2vaccineinduceshighlevelsofantibodiesandprotectsrhesusmacaques |